The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial - Hadji, Peyman; Marmé, Frederik; Schneeweiss, Andreas (Journal of bone oncology, 2019)
Available online 2 October 2018